Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815 for patients with psoriasis and atopic dermatitis, rheumatoid arthritis, and ulcerative colitis/crohn's colitis; and EDP1503 for the treatment of colorectal cancer, renal cell carcinoma, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:EVLO
CUSIPN/A
Phone617-577-0300
Debt
Debt-to-Equity Ratio0.09
Current Ratio24.08
Quick Ratio24.08
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees59
Outstanding Shares31,740,000
Market Cap$416.77 million
Evelo Biosciences (NASDAQ:EVLO) Frequently Asked Questions
What is Evelo Biosciences' stock symbol?
Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO."
How were Evelo Biosciences' earnings last quarter?
Evelo Biosciences Inc (NASDAQ:EVLO) announced its quarterly earnings results on Thursday, August, 2nd. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.50. View Evelo Biosciences' Earnings History.
When is Evelo Biosciences' next earnings date?
What price target have analysts set for EVLO?
4 brokers have issued twelve-month target prices for Evelo Biosciences' shares. Their predictions range from $25.00 to $26.00. On average, they anticipate Evelo Biosciences' stock price to reach $25.50 in the next twelve months. This suggests a possible upside of 92.9% from the stock's current price. View Analyst Price Targets for Evelo Biosciences.
What is the consensus analysts' recommendation for Evelo Biosciences?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Evelo Biosciences.
Who are some of Evelo Biosciences' key competitors?
Some companies that are related to Evelo Biosciences include Aimmune Therapeutics (AIMT), Allakos (ALLK), Theravance Biopharma (TBPH), Corcept Therapeutics (CORT), ARMO Biosciences (ARMO), Amneal Pharmaceuticals (AMRX), Arrowhead Pharmaceuticals (ARWR), TESARO (TSRO), Myovant Sciences (MYOV), IMMURON Ltd/S (IMRN), Innoviva (INVA), Impax Laboratories (IPXL), Deciphera Pharmaceuticals (DCPH), ImmunoGen (IMGN) and Alder Biopharmaceuticals (ALDR).
Who are Evelo Biosciences' key executives?
Evelo Biosciences' management team includes the folowing people:
- Dr. Noubar B. Afeyan Ph.D., Co-founder & Chairman (Age 55)
- Dr. Balkrishan Gill, Pres, CEO & Director (Age 53)
- Dr. Mark Bodmer, Chief Scientific Officer and Pres of R&D (Age 60)
- Dr. Duncan McHale M.D., Ph.D., Chief Medical Officer (Age 51)
- Mr. Jonathan Poole, Chief Financial Officer (Age 43)
When did Evelo Biosciences IPO?
(EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.
When does the company's lock-up period expire?
Evelo Biosciences' lock-up period expires on Monday, November 5th. Evelo Biosciences had issued 5,312,500 shares in its IPO on May 9th. The total size of the offering was $85,000,000 based on an initial share price of $16.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.
Has Evelo Biosciences been receiving favorable news coverage?
News articles about EVLO stock have been trending positive on Wednesday, according to Accern. The research group ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Evelo Biosciences earned a news and rumor sentiment score of 0.26 on Accern's scale. They also assigned news headlines about the company an impact score of 45.18 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next few days. View Recent Headlines for Evelo Biosciences.
Who are Evelo Biosciences' major shareholders?
Evelo Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Flagship Pioneering Inc. (57.45%), FMR LLC (10.43%), HARBOURVEST PARTNERS L.P. (5.50%), HarbourVest Partners LLC (5.56%), DEMENTIA DISCOVERY LP (8.30%) and BlackRock Inc. (0.82%). View Institutional Ownership Trends for Evelo Biosciences.
Which institutional investors are buying Evelo Biosciences stock?
EVLO stock was purchased by a variety of institutional investors in the last quarter, including Flagship Pioneering Inc., FMR LLC, HarbourVest Partners LLC, BlackRock Inc., Laurion Capital Management LP, ARK Investment Management LLC, Victory Capital Management Inc. and Dean Capital Investments Management LLC. View Insider Buying and Selling for Evelo Biosciences.
How do I buy shares of Evelo Biosciences?
Shares of EVLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Evelo Biosciences' stock price today?
One share of EVLO stock can currently be purchased for approximately $13.22.
How big of a company is Evelo Biosciences?
Evelo Biosciences has a market capitalization of $416.77 million. Evelo Biosciences employs 59 workers across the globe.
How can I contact Evelo Biosciences?
Evelo Biosciences' mailing address is 620 Memorial Drive Suite 200 West, Cambridge MA, 02139. The company can be reached via phone at 617-577-0300 or via email at [email protected]
MarketBeat Community Rating for Evelo Biosciences (NASDAQ EVLO)
MarketBeat's community ratings are surveys of what our community members think about Evelo Biosciences and other stocks. Vote "Outperform" if you believe EVLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
